Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon May 01, 2024 4:28pm
94 Views
Post# 36018165

RE:RE:Inflation Reduction Act (IRA) boosts biological drugs

RE:RE:Inflation Reduction Act (IRA) boosts biological drugs I have sufficiently described the significance of the passing of the IRA and the changes in international regulations in favor of ONCY and ONCY's biologic platform drug pelareorep, which has been granted Orphan/Rare drug status and has been trialed in diseases with 'unment treatment needs'', such as PDAC and mBC. I have described these advantages in detail, yet I have now come to understand that some have been posting their opinions on matters that they don't seem to understand whatsoever. I cannot say it more politely other than to suggest that those same persons go back and start reading what I had alread posted, highlighted and collated, with cited refereces for easy access, and which others have criticized me for 'cutting and pasting'.
<< Previous
Bullboard Posts
Next >>